Board of Directors

Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. Brad has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.

Brad is also a director of Cogstate Inc. and Cogstate Sport Inc. Prior to taking the position of CEO at Cogstate, Brad joined Cogstate as Chief Financial Officer and Company Secretary in May 2004. Prior to that, Brad held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. Brad is a chartered accountant who holds a Bachelor of Business degree.

Martyn Myer (BMEng, MESc, MSM) is Chairman of Cogstate Limited. Mr Myer also chairs the Remuneration and Nomination Committee and the Audit and Compliance Committee. Until 30 June 2007 he was President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of the Florey Neuroscience Institutes until May 2009.

In 2008, Mr Myer was awarded the title of Officer of the Order of Australia for service to business and the community, particularly through contributions to medical research and the establishment of the Florey Neuroscience Institutes and through executive and philanthropic roles with a range of organisations.

At the Howard Florey Institute he participated in the transition of the Institute’s research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. Mr Myer was appointed to the Council of the University of Melbourne in February 2009. Mr Myer obtained his Master of Science in Management at MIT in Boston, and his Master of Engineering Science at Monash University, Melbourne.

During the last three years, Mr Myer has also served as a director of the following listed companies:

• Diversified United Investment Ltd
• SP Australia Networks (Transmission) Ltd
• SP Australia Networks (Distribution) Ltd

David Dolby (MBA, Stanford Graduate School of Business; BSE, Duke University) is a non-executive director. He is an independent investor representing the Dolby Family Trust on a variety of technology investments in pharmaceutical research and drug development, health monitoring devices, computer vision, aerospace, consumer media and entertainment technologies, as well as philanthropic ventures for the Ray and Dagmar Dolby Family Fund. Currently, he is engaged in a variety of grant making and impact investments in the pursuit of accelerating detection and cures for Alzheimer’s disease. He is a director of Dolby Laboratories, Inc., a global technology firm with solutions for audio, video, and voice applications.

Previously he was a manager at Dolby Laboratories in business development focused on strategic partnerships and technology standards. He has held a variety of technology analyst, product management, and engineering positions across investment banking, Internet network software, high performance media server, and design and engineering industries.

David Simpson (BA, Hons) is an independent non-executive Director. He sits on the Audit and Compliance Committee as well as the Remuneration and Nomination Committee. Most recently he was the CEO of the Bluearth Institute, a Melbourne based not-for-profit enterprise established to develop programs that promote health and fitness through increased physical activity.

Previously he was Senior Partner at Doremus Communications, the largest US business to business agency. From 1985 to 2001 he held a series of senior management positions in Asia, South Africa and North America as well as Australia for the multinational advertising agency, J.Walter Thompson.

Mr van den Broek (Graduate of Harvard University, CFA) is an independent non-executive director. He is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies.

From 2000 through 2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to that Mr. van den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist.

Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development Team. Before joining Eli Lilly in 2002, Richard spent 23 years with the Mount Sinai School of Medicine in NY where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center.

Dr. Mohs received a Ph.D. in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School. He is the author or co-author of over 350 scientific papers, including those describing clinical trials that lead to the approval, in the US and other countries, of cholinergic drug treatments for Alzheimer’s disease.

Dr. Mohs is currently Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation, a patient-centered, non-profit organization devoted to enhancing the speed and quality with which new treatments for Alzheimer’s disease are developed. Richard also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is
a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation.

Until mid-2015, Jane was part of the Group Management Committee of BHP Billiton as President, Governance and Group Company Secretary from 2013, having been Group Company Secretary from 2007. Prior to joining BHP Billiton in 2006, Jane was part of the executive team at AGL as Group Manager External and Regulatory Services and Group Company Secretary.

Jane is currently a Non-Executive Director of Healthscope Ltd and Energy Australia Pty Ltd.

Jane previously held various Australian State and Commonwealth Government positions, including Director General NSW Ministry of Energy and Utilities, Deputy Director General NSW Cabinet Office as well as senior executive roles in Rail, Land & Water Conservation and Forestry. She previously worked in private legal practice.

Jane has a Bachelor of Economics (Hons) & Bachelor of Laws from Monash University and Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Australian Institute of Company Directors.